Back to News
Market Impact: 0.15
Phathom Defends VOQUEZNA Exclusivity As FDA Seeks Comments On Generic Drug Dispute; Stock Down
Source: Nasdaq
Regulation & LegislationLegal & Litigation
Phathom Pharmaceuticals said the FDA opened a public docket seeking comments on legal and regulatory issues raised in BDR Pharmaceuticals International's lawsuit against the agency. The report provides no outcome, deadline, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Iran’s anti-negotiation hardliners turn against President Pezeshkian
- ‘Imposed significant financial harm’: 20 states join the FTC in suing Dollar General for ‘deceptive pricing practices’ despite ‘corporate knowledge’
- Anthropic publicly files for listing on the US stock market
- Spain Eases Data Center Energy Rules in Win for Big Tech
- Israeli election draws tens of thousands of citizens flying back to vote